One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany
Authors' conclusion
This large real-world analysis confirms the relevance of the DBLG1 automated insulin delivery solution for the achievement of standards of care in adult patients with type 1 diabetes.
Study context
- Population
- Adults with T1D equipped with the DBLG1 system in Germany before 30 April 2022, with ≥14 days of closed-loop usage; 41% women, age 45.1 ± 14.5 years
- Participants
- 3,706 adults
- Outcome
- TIR (70-180 mg/dl), median
- Follow-up
- Mean 131.0 ± 85.1 days
Methodological detailsreal-world, single-group
- Real-world
- Single-group
Main finding
As reported in the abstract
- Median % TIR (70-180 mg/dl)
- 72.1% (IQR 65.0-78.9)
- Time <70 mg/dl
- 0.9% (0.5-1.7)
- Time <54 mg/dl
- 0.1% (0.1-0.3)
- Median GMI
- 7.0% (6.8-7.3)
- Median time in closed-loop
- 95.0% (IQR 89.1-97.4)
Observational data: associations, not effects.
Further findings
Mean TIR by baseline HbA1c (exploratory, subset with baseline HbA1c)
- Baseline HbA1c, median (IQR 6.9-8.0)
- 7.4%
- Mean TIR, baseline A1c ≥8.5%
- 65.8 ± 9.9%
- Mean TIR, baseline A1c <6.5%
- 81.3 ± 6.8%
- Exploratory analysis
- n = 2460
Original publication
One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab. Published 21 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →